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Abstract: Proton therapy (PT) is a treatment with high dose conformality that delivers a highly-focused
radiation dose to solid tumors. Targeted radionuclide therapy (TRT), on the other hand, is a systemic
radiation therapy, which makes use of intravenously-applied radioconjugates. In this project, it was
aimed to perform an initial dose-searching study for the combination of these treatment modalities
in a preclinical setting. Therapy studies were performed with xenograft mouse models of folate
receptor (FR)-positive KB and prostate-specific membrane antigen (PSMA)-positive PC-3 PIP tumors,
respectively. PT and TRT using 177Lu-folate and 177Lu-PSMA-617, respectively, were applied either
as single treatments or in combination. Monitoring of the mice over nine weeks revealed a similar
tumor growth delay after PT and TRT, respectively, when equal tumor doses were delivered either
by protons or by β¯-particles, respectively. Combining the methodologies to provide half-dose by
either therapy approach resulted in equal (PC-3 PIP tumor model) or even slightly better therapy
outcomes (KB tumor model). In separate experiments, preclinical positron emission tomography
(PET) was performed to investigate tissue activation after proton irradiation of the tumor. The
high-precision radiation delivery of PT was confirmed by the resulting PET images that accurately
visualized the irradiated tumor tissue. In this study, the combination of PT and TRT resulted in an
additive effect or a trend of synergistic effects, depending on the type of tumor xenograft. This study
laid the foundation for future research regarding therapy options in the situation of metastasized
solid tumors, where surgery or PT alone are not a solution but may profit from combination with
systemic radiation therapy.
Keywords: proton therapy; targeted radionuclide therapy; PET imaging; folate receptor; PSMA;
177Lu; combination therapy
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1. Introduction
Cancer in patients often has two disease components: loco-regional and disseminated. The primary
tumor and immediate microscopic spread in the surrounding tissue is referred to as loco-regional
disease, whereas disseminated disease can typically be metastatic in nature or disease that has spread
to remote sites through the lymphatic system. As such, different treatment strategies often need to be
applied to these different components.
Proton therapy (PT) is a curative radiation therapy modality for the treatment of loco-regional
disease, which makes use of a proton beam delivering a highly-focused radiation dose to the primary
tumor. A major advantage over external beam photon radiotherapy is the possibility of a precise
deposition of the proton radiation dose, based on the maximum energy loss and final stopping of
protons at a specific depth (“Bragg peak”) [1]. Consequently, this spares the normal tissue in the
vicinity of the target volume. On the other hand, targeted radionuclide therapy (TRT) is a systemic
treatment approach primarily for disseminated disease that makes use of intravenously-applied
radioconjugates, which accumulate selectively in cancer tissue due to specific targeting of tumor
cell-associated receptors or antigens. This concept is routinely applied in clinics with, for example,
somatostatin receptor-targeted peptides (such as Lutathera™, 177Lu-DOTATATE, and somatostatin
analog [2]) for the treatment of neuroendocrine tumors, as well as with antibodies to target CD20 (e.g.,
Zevalin™ and 90Y-Ibritumomab tiuxetan [3]) for the treatment of Non-Hodgkin’s lymphoma. More
recently, the application of the 177Lu-PSMA-617 has shown promising results in metastasized prostate
cancer patients [4], which prompted the initiation of a Phase III clinical trial (NCT03511664). TRT can
be curative for oligo-metastatic disease and has shown benefit to extend the survival time of patients
with end-stage disease and provide them with an improved quality of life. Off-target accumulation of
radioconjugates may, however, cause a risk of damage to radiosensitive healthy tissue such as the bone
marrow and the kidneys, which present the dose-limiting factors in TRT [5,6].
As such, patients with metastatic disease may profit from a therapy paradigm that combines proton
beam irradiation of the local tumor and TRT for the treatment of metastases, including micro-metastases
that are not detectable with current imaging modalities. This combination could be of particular
interest, as the substantially-reduced dose to normal tissues resulting from proton therapy could be of
great advantage when combined with a more systemic, and less localized, treatment such as TRT. Such
combination therapies have, however, not been extensively investigated to date. On the other hand,
several preclinical and clinical studies have been reported in the literature, in which the combination
of external photon beam radiation therapy and targeted TRT was investigated [7,8].
The unique situation at the Paul Scherrer Institute, where the Center for Proton Therapy (CPT)
and the Center for Radiopharmaceutical Sciences (CRS) are co-localized, offers the possibility to
assess these combined treatments. At CRS, a major research focus has been the development and
application of folate-based radioligands for targeting folate receptor (FR)-positive tumor types, as
well as radioligands for targeting prostate-specific membrane antigen (PSMA)-expressing prostate
cancer [9–12]. FR- and PSMA-targeting agents have been developed at CRS and optimized in terms of
their pharmacokinetic properties to make them highly effective for TRT, as demonstrated in preclinical
experiments [12–14]. Both types of small-molecular mass radioligands have potential for future clinical
translation. Similarly, CPT has established itself in the international community as the state-of-the-art
proton therapy center, largely due to its pioneering gantry technologies and the development of Pencil
Beam Scanning (PBS) [15,16]. The application of PBS to treat cancer patients is world-renowned and
has demonstrated its clinical efficacy in a significant number of successfully-treated individuals, as
documented in several publications [17–19]. One of the most successful programs of CPT is, however,
the fixed horizontal beam line OPTIS2, which has been used for the treatment of ocular melanoma and
other eye-located tumors since 1984. Using single- and double-scattered-collimated beams, proton
treatments at OPTIS2 result in an overall local control of more than 98% after five years [20,21].
The aim of this study was to investigate the potential of combining PT and TRT in a preclinical
setting, with the aim of establishing equi-equivalent dose levels between the two modalities and
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to additionally investigate potential additive or synergistic effects. In this proof-of-concept study
with tumor-bearing mice, PT and 177Lu-based TRT were, therefore, applied separately, as well as
in combination, to two different tumor mouse models using 177Lu-folate developed at CRS or the
clinically-applied 177Lu-PSMA-617.
2. Materials and Methods
2.1. In Vivo Experiments
In vivo experiments were performed by respecting all applicable international, national, and/or
institutional guidelines for the care and use of animals. In particular, all animal experiments were
carried out according to the guidelines of Swiss Regulations for Animal Welfare. The preclinical studies
were ethically approved by the Cantonal Committee of Animal Experimentation and permitted by
the responsible cantonal authorities (No. 75691, July 2016). Athymic female nude mice (CD-1) at
the age of 5–6 weeks, obtained from Charles River Laboratories (Sulzfeld, Germany), were used for
studies involving 177Lu-folate. In this case, mice were fed with a folate-deficient rodent diet (ssniff
Spezialdiäten GmbH, Soest, Germany). BALB/c nude mice at the age of 5–6 weeks were also obtained
from Charles River Laboratories (Sulzfeld, Germany) and used for studies involving 177Lu-PSMA-617.
These mice were fed with a standard rodent diet (Kliba Nafag, Granovit AG, Kaiseraugst, Switzerland).
2.2. Preparation of Mice
The details of cell culture in order to prepare the cells for inoculation are reported in the
Supplementary Material. KB (cervical carcinoma cell line, subclone of HeLa cells, ACC-136) and PC-3
PIP tumor cells (subline of the androgen-independent PC-3 human prostate cancer cell line, kindly
provided by Prof. Dr. Martin Pomper, Johns Hopkins University School of Medicine, Baltimore, MD,
USA) were used in this study.
Preparation of mice for the therapy studies: CD1 nude mice were inoculated with KB tumor cells
(4.5 × 106 cells in 100 µL PBS) in the subcutis of the left shoulder 4 days before therapy start (Study I).
BALB/c nude mice were prepared by inoculation of PC-3 PIP tumors (4.0 × 106 cells in 100 µL Hank’s
balanced salt solution; HBSS) in the subcutis of the left shoulder 6 days before therapy start (Study II).
Preparation of mice for PET imaging: Two CD1 nude mice were inoculated with KB tumor
cells (4.5 × 106 cells in 100 µL PBS) into the subcutis of each shoulder. Two BALB/c nude mice were
inoculated with PC-3 PIP tumor cells (4.0 × 106 in 100 µL HBSS) into the subcutis of each shoulder,
respectively. In both mouse models, PET/CT imaging of the tissue, activated by proton irradiation, was
performed 16 days after tumor cell inoculation.
2.3. Irradiation Station for Mice
A mouse irradiation platform was fabricated and positioned at OPTIS2 of CPT for proton
irradiations. A support for the mouse was designed and built to fit the requirements of OPTIS2
geometry. The support was fixed to a metallic device which could be moved with 6 degrees of freedom
by the robotic chair used for patient treatment. The beam was shaped according to the dimension
of each tumor using cylindrical copper collimators. The compact design of the support allowed the
placing of the mouse as close as possible to the collimators, thereby allowing an accurate position
with an error margin smaller than 1 mm. Two co-axial tubes placed in front of the mouse head were
designed to provide inhalation anesthesia (Figure 1).
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Figure 1. Picture of an anesthetized tumor-bearing mouse positioned on the irradiation platform 
installed at OPTIS2 at CPT for proton irradiation. (a) Frontal view with beam nozzle in the center of 
the picture and the inhalation anesthesia on the right side. (b) Top view with the beam nozzle on the 
left side and the mouse bed on the right side. Direction of beam is indicated by a white arrow. 
2.4. Irradiation of Tumor-Bearing Mice with Protons 
The set-up of the irradiation facility for the mice and the precise procedure of the experiments 
are described in the Supplementary Material. The aim of the experimental set-up was to obtain a 
homogeneous absorbed dose to the tumor and minimize the absorbed dose to the surrounding tissue. 
A homogeneous dose was delivered to cover the entire tumor, but sparing the surrounding tissues. 
All irradiations were performed using a 2.5-mm safety margin to account for possible inaccuracies 
during positioning, movement of the mouse and other uncertainties, as is used clinically with this 
facility. The procedure was simplified by considering the tumors in the mice as spheres with a 
diameter equal to the biggest diameter of the actual tumor, as measured the day before the 
irradiation. Both mean absorbed dose and range (the deepest point of treatment) of the proton beam 
were specified for each individual mouse. An extra 2.5-mm posterior margin was applied, to account 
for the distal uncertainties of the proton beam. A full modulation of the beam was implemented in 
all cases, meaning that all the tissue, from the surface of the mouse to the point defined by the range, 
was irradiated. All parameters were used to create irradiation steering files specific to each mouse, 
that were individually verified using a test phantom, to ensure the delivery of the treatment 
prescribed in each case. 
Mice were anesthetized by inhalation anesthesia using a mixture of isoflurane and oxygen. Mice 
were positioned for the irradiation by using both in-room mounted lasers and calibrated images 
acquired by the beam eye view camera installed in the OPTIS2 nozzle. This allowed the adjust of the 
position of the robotic chair to which the mouse bed was fixed until the center of the tumor appeared 
in the center of the field. Once the mouse was positioned, the irradiation was initiated by delivering 
the prescribed dose in 20–40 s. 
2.5. Preparation and Application of 177Lu-Labeled Radioligands  
The chemical structures of the ligands and detailed methods of radiolabeling, including quality 
control, are reported in the Supplementary Material (Figure S1). The development of the DOTA-folate 
conjugate (previously referred to as “cm10”) and 177Lu-labeling was previously published by 
Siwowska et al. [22]. Radiolabeling of PSMA-617 was carried out as previously reported by Benešová 
et al. [11]. The respective biodistribution data of these radioligands in KB and PC-3 PIP tumor mouse 
models, respectively, are summarized in the Supplementary Material (Tables S1 [22] and S2 [11]). 
177Lu-folate and 177Lu-PSMA-617, respectively, were prepared at molar activities that resulted in a 
ligand quantity of 1 nmol per mouse in order to guarantee equal tissue distribution of the 
radioligands, irrespective of the injected activity. 
  
Figure 1. Picture of an anesthetized tumor-bearing mouse positioned on the irradiation platform
installed at OPTIS2 at CPT for proton irradiation. (a) Frontal view with beam nozzle in the center of the
picture and the inhalation anesthesia on the right side. (b) Top view with the beam nozzle on the left
side and the mouse bed on the right side. Direction of beam is indicated by a white arrow.
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2.5. Preparation and Application of 177Lu-Labeled Radioligands
The chemical structures of the ligands and detailed methods of radiolabeling, including
quality control, re eport d in the Supplementary Material (Figure S1). The development of the
DOTA-folate conjugate (previously r ferred to as “cm10”) and 177Lu-labeling was previously published
by Siwowska et al. [22]. Radiolabeling of PSMA-617 was carried out as previously reported
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Tabl S2 [11]). 177Lu-folate and 177Lu-PSMA-617, respectivel , wer prepared at molar activities that
res lted in a ligand quantity of 1 nmol per mouse in order to guarantee equal tissue distribution of the
radioligands, irrespective f th injected activity.
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2.6. Dosimetric Calculations for TRT
In contrast to PT, where the delivered dose distribution can be precisely calculated and measured
as part of the standard quality assurance program of the OPTIS2 facility, the dosimetry of TRT is
more challenging. As such, biodistribution data, previously published for 177Lu-cm10 [22] and
177Lu-PSMA-617 [11], respectively, were converted to non-decay-corrected data and used to calculate
the mean absorbed doses to the KB and PC-3 PIP tumors, respectively, as previously reported [22]. The
mean specific absorbed dose (Gy/MBq) to the tumor xenografts was calculated by multiplication of the
time-integrated activity concentration by the emitted electron energy per decay, the absorbed fraction
of the emitted electron energy, and a conversion factor. In the case of 177Lu-folate, linear integration
of the first time points was used for the time-integrated activity concentration between 0 and 24 h
post injection (p.i.). The time-integrated activity concentration from 24 h to infinity was calculated by
integration of a mono-exponential function. In the case of 177Lu-PSMA-617, a linear function was used
for the time interval 0–8 h p.i. and a bi-exponential function for the time points 8–196 h p.i. for the
tumor. The time-integrated activity concentration was obtained by integration to infinity.
The absorbed fractions for the tumors (40−50 mg) were assessed by Monte Carlo simulations
using PENELOPE-2014 [23]. In the simulations, a uniform activity distribution within the tumors was
assumed. The emitted electron energy per decay for 177Lu was 147 keV (www.nndc.bnl.gov).
2.7. Therapy Studies
Two therapy studies were performed with mice irradiated with protons (PT) or treated with
177Lu-folate or 177Lu-PSMA-617 (TRT), respectively, or the combination of these two modalities.
The dose to the tumors was chosen based on our experience with TRT using 177Lu-folate and
177Lu-PSMA-617, respectively. The monotherapy with either therapy modality was aimed at delaying
the tumor growth, but not to eradicate tumor xenografts entirely in order to enable the determination
of potential additive or synergistic effects of the combination therapy. In each experiment, four groups
of mice were included and treated at Day 0 of the study. The first group of mice underwent sham
irradiation (without delivering proton irradiation) and was injected with only saline (Group A: control).
The second and third groups, respectively, were treated with protons only (Group B: PT) or with
177Lu-folate or 177Lu-PSMA-617 only (Group C: TRT). The fourth group received the combination
therapy (Group D: PT and TRT) (Table 1).
Table 1. Study designs of the therapies using PT and TRT through use of 177Lu-folate (Study I) or
177Lu-PSMA-617 (Study II).
Study I: KB Tumor Mouse Model
Groups A: Control B: PT C: TRT D: PT and TRT
Proton Irradiation Sham irradiation Irradiation: 15 Gy Sham irradiation Irradiation: 7.5 Gy
177Lu-Folate
Treatment
Saline injection Saline injection
177Lu-folate 15 Gy
(17 MBq) 1 nmol/mouse
177Lu-folate 7.5 Gy
(8.5 MBq) 1 nmol/mouse
Number of Mice n = 13 n = 11 n = 11 n = 11
Study II: PC-3 PIP Tumor Mouse Model
Groups A: Control B: PT C: TRT D: PT and TRT
Proton Irradiation Sham irradiation Irradiation: 10 Gy Sham irradiation Irradiation: 5.0 Gy
177Lu-PSMA-617
Treatment
Saline injection Saline injection
177Lu-folate: 10 Gy
(2.5 MBq) 1 nmol/mouse
177Lu-folate: 5.0 Gy
(1.25 MBq) 1 nmol/mouse
Number of Mice n = 11 n = 11 n = 11 n = 11
In Study I, PT was applied at doses of 15 Gy and 7.5 Gy for single and combination therapy,
respectively, and TRT was applied at 17 MBq 177Lu-folate (corresponding to 15 Gy) and 8.5 MBq
177Lu-folate (corresponding to 7.5 Gy) for single and combination therapy, respectively. In Study II,
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PT was applied at doses of 10 Gy and 5 Gy for single and combination therapy, respectively, and
TRT was applied at 2.5 MBq 177Lu-PSMA-617 (corresponding to 10 Gy) and 1.25 MBq 177Lu-folate
(corresponding to 5 Gy) for single and combination therapy, respectively. The radioligands were
applied intravenously in a lateral tail vein in a volume of 100 mL saline.
The mice were monitored by measuring body weights and the tumor size every other day over
9 weeks. Mice were euthanized when pre-defined endpoint criteria (see below) were reached, or when
the study was terminated at Day 63. The relative body weight (RBW) was defined as [BWx/BW0],
where BWx is the body weight in grams at a given Day x and BW0 the body weight in grams at Day 0.
The tumor dimension was determined by measuring the longest tumor axis (L) and its perpendicular
axis (W) with a digital caliper. The tumor volume (V) was calculated according to the equation [V =
0.5 × (L × W2)]. The relative tumor volume (RTV) was defined as [TVx/TV0], where TVx is the tumor
volume in mm3 at a given Day x and TV0 the tumor volume in mm3 at Day 0.
The endpoint criteria were set according to the size of the mouse strain. In Study I, they were
defined as: (i) a tumor volume >1000 mm3; (ii) body weight loss of ≥15%; (iii) tumor volume of
≥900 mm3 and body weight loss of ≥10%; or (iv) signs of unease and discomfort. The endpoint criteria
in Study II were defined as: (i) a tumor volume ≥800 mm3; (ii) body weight loss of ≥15%; (iii) tumor
volume of ≥700 mm3 and body weight loss of ≥10%; or (iv) signs of unease and discomfort.
2.8. Assessment of the Therapy Studies
The efficacy of each treatment modality alone or in combination was expressed as the tumor
growth delay (TGDx), which was calculated as the time required for the tumor volume to increase
x-fold over the initial volume at Day 0. The tumor growth delay index [TGDIx = TGDx(T)/TGDx(C)]
was calculated as the TGDx ratio of treated mice (T) over control mice (C) for a 2-fold (x = 2, TGD2)
and 5-fold (x = 5, TGD5) increase of the initial tumor volume. The median survival was calculated
using GraphPad Prism software (version 7).
The data (average survival time, TGDI2 and TGDI5) were analyzed for significance as indicated in
Section 3 using a one-way ANOVA with Tukey’s multiple comparison post-test using GraphPad Prism
software (version 7). A value of p < 0.05 was considered statistically significant. Survival of mice was
assessed using Kaplan–Meier curves to determine median survival of mice of each group using Graph
Pad Prism software (version 7).
2.9. PET Imaging
PET/CT scans were performed using a small-animal bench-top PET/CT scanner (G8, Perkin Elmer,
Waltham, MA, USA.) in order to qualitatively estimate the delivered dose distribution by PT [24]).
Due to the compact size of this scanner, it was possible to transport it from CRS to CPT to the OPTIS2
treatment room. PET/CT imaging studies were performed with mice bearing KB tumors or PC-3 PIP
tumors, respectively, on each shoulder. The left tumor xenograft of each mouse was irradiated with
protons at a dose of 20 Gy. Immediately afterwards, the mouse was placed on the PET animal bed and
moved into the scanner (Figure S2). Static whole-body PET scans of 10 min duration were performed
followed by a CT of 1.5 min. During the in vivo scans, the mice were anesthetized with a mixture
of isoflurane and oxygen. Reconstruction of acquired data was performed using the software of the
provider of the G8 scanner. All images were prepared using VivoQuant post-processing software
(version 3.0, inviCRO Imaging Services and Software, Boston, MA, USA). A Gauss post-reconstruction
filter was applied (FWHM = 1 mm) to the images, which were presented with the scale adjusted by
cutting 5% of the lower scale in order to allow visualization of the most important organs and tissues.
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3. Results
3.1. Dosimetry Estimation for TRT Using 177Lu-Folate and 177Lu-PSMA-617
The mean absorbed tumor dose for 177Lu-cm10 was 0.89 Gy/MBq, as previously published by
Siwowska et al. [22], which corresponded to an absolute dose of ~7.5 Gy and ~15 Gy when injecting
8.5 MBq or 17 MBq 177Lu-folate, respectively. The mean absorbed tumor dose for 177Lu-PSMA-617 was
4.0 Gy/MBq, which corresponded to an absolute dose of ~5 Gy and ~10 Gy when injecting 1.25 MBq or
2.5 MBq 177Lu-PSMA-617, respectively. The numbers calculated for the mean absorbed tumor dose
delivered by TRT can be considered as a dose estimation rather than an exact value, as is the case when
using external proton beam radiation therapy (PT).
3.2. Therapy Studies
3.2.1. Therapy Study I: Combination Proton Therapy and 177Lu-Folate Therapy
In the first study, CD1 nude mice inoculated with KB tumor cells, were treated with PT, TRT or
a combination of both. A relatively fast KB tumor growth was observed in untreated control mice
(sham-irradiated and injected with saline; Group A). This resulted in two mice to reach the endpoint
at Day 16, while the last mouse was euthanized at Day 36. The tumor growth of treated mice was
delayed and resulted in the first mouse of Group B to reach an endpoint at Day 42 while in Group C
this was the case at Day 30. In Groups B and C, 8 mice out of 11 were still alive at study end on Day 64.
Interestingly, none of the mice of the combination therapy (Group D) reached an endpoint within the
64 days of monitoring (Table 2 and Figure 2a). As compared to control mice of Group A, the time to
reach a relative tumor volume of 2 (TGDI2) was, with 3.5-, 3.2- and 4.2-fold, significantly (p < 0.05)
longer for mice of the treated groups (Groups B–D). A significant difference among the TGDI2 values
among groups of treated mice was only observed for Groups C and D (p < 0.05). The same significance
was also found for the calculated TGDI5. The median survival time of control mice (Group A) was 30
days, however, in all other groups (Groups B–D), the median survival remained undefined since more
than 50% of the mice were still alive at study end (Table 2 and Figure 2b). The body weight of mice
increased in all groups over time, indicating that the therapies were well tolerated (Figure 2c).
3.2.2. Therapy Study II: Combination of Proton Therapy and 177Lu-PSMA-617 Therapy
In the second study, BALB/c nude mice inoculated with PC-3 PIP-cells were treated with PT, TRT
or a combination of both. A relatively fast tumor growth was observed in untreated control mice
(sham-irradiated and injected with saline; Group A), which led the first mouse to reach the endpoint
already on Day 14. The tumor growth of all treated groups was slower, resulting in the first mice
to be euthanized at Day 26 (Groups B and C) and Day 32 (Group D), respectively. While in Group
A all mice reached an endpoint within the 36 days of investigation, one mouse in each of Groups B
and D and three mice in Group C were still alive at the end of the study (Table 2 and Figure 2d). To
reach a relative tumor volume of 2 (TGDI2), the time was 3.3–3.8-fold (p < 0.05) longer for treated mice
(Groups B–D) as compared to control mice of Group A. There was, however, no significant difference
(p > 0.05) determined among each of the treated groups (Groups B–D; Table 2). The same findings
held true for the TGDI5 which was significantly (p < 0.05) increased in treated groups (Groups B–D) as
compared to control mice of Group A, but no significant difference (p > 0.05) was found among the
treated groups (Groups B–D). The median survival time of mice treated with 10 Gy of either therapy
modality (Groups B and C) or the combination (Group D) was in the range of 42–50 days which was
clearly longer than for control mice (Group A: median survival, 24 days). The longest median survival
time was observed in mice that received 177Lu-PSMA-617 (Group C: 50 days) (Table 2 and Figure 2e).
In line with these findings, the average survival was significantly longer (p < 0.05) for treated mice
than for control mice, but there was no significant difference in the average survival among the single
Pharmaceutics 2019, 11, 450 8 of 13
therapy groups (Groups B–D). The body weight was relatively constant in treated mice, but control
mice lost body weight over time, presumably due to the increasing tumor burden (Figure 2f).Pharmaceutics 2019, 11, x 8 of 13 
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Figure 2. Graphs showing average relative tumor volume of each group until the first mouse of each
group had to be euthanized, the median survival and the relative body weight of mice of: Study I (a–c);
and Study II (d–f). Control mice (control; pink), mice treated with protons (PT; yellow), mice treated
with 177Lu-folate (TRT; blue) and the combination of these modalities (PT and TRT; green). (a,d) Tumor
growth curves shown as average of all mice of one group until the first mouse of each group had to be
euthanized; (b,e) Kaplan–Meier survival curves; and (c,f) relative body weights.
3.3. PET-Based Imaging of Tissue Activation after Proton Irradiation
Tissue activation upon irradiation of the mice with protons was demonstrated using PET/CT.
Mice were kept still under anesthesia and scanned immediately (approximately 3 min) after proton
irradiation. PET/CT images with either tumor mouse model showed highly focused regions of tissue
activation in the tumor located on the left side of the animal, qualitatively demonstrating the high dose
conformation to the tumor of the proton treatments. On the other hand, no PET signal was detected in
the tumor which was not irradiated, located on the right shoulder of the mouse (Figure 3).
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Table 2. Parameters characterizing the efficacy of the applied therapy. (A) Study I: Investigation of
KB tumor-bearing CD1 nude mice. (B) Study II: Investigation of PC-3 PIP tumor-bearing BALB/c
nude mice.
Study I: KB Tumor Mouse Model
Group TumorDose (Gy)
First Mouse
Euthanized
(Day)
Last Mouse
Euthanized
(Day)
Median
Survival
(days)
Average Survival
(days) TGDI2 TGDI5
A: Saline - 16 36 30 27 ± 9(n = 13)
1.0 ± 0.4
(n = 13)
1.0 ± 0.3
(n = 13)
B: PT 15 42 64 (study end) not reached n = 3 (endpoint)
1
n = 8 (alive) 2
3.5 ± 1.1
(n = 11)
2.7 ± 0.7
(n = 9)
C: TRT ~15 30 64 (study end) not reached n = 3 (endpoint)
1
n = 8 (alive) 2
3.2 ± 1.1
(n = 10)
2.4 ± 0.9
(n = 10)
D: PT &
TRT 7.5 + ~7.5 none 64 (study end) not reached
n = 0 (endpoint) 1
n = 11 (alive) 2
4.2 ± 0.6
(n = 11)
3.2 ± 0.2
(n = 11)
Study II: PC-3 PIP Tumor Mouse Model
Group TumorDose (Gy)
First Mouse
Euthanized
(Day)
Last Mouse
Euthanized
(Day)
Median
Survival
(days)
Average Survival
(days) TGDI2 TGDI5
A: Saline - 14 34 24 26 ± 6(n = 11)
1.0 ± 0.5
(n = 11)
1.0 ± 0.4
(n = 10)
B: PT 10 26 64 (study end) 42 n = 10 (endpoint)
1
n = 1 (alive) 2
3.3 ± 1.5
(n = 11)
2.3 ± 0.4
(n = 8)
C: TRT ~10 26 64 (study end) 50 n = 8 (endpoint)
1
n = 3 (alive) 2
3.8 ± 2.1
(n = 9)
1.7 ± 0.6
(n = 6)
D: PT &
TRT 5.0 + ~5.0 32 64 (study end) 42
n = 10 (endpoint) 1
n = 1 (alive)
3.6 ± 1.3
(n = 11)
2.1 ± 0.6
(n = 11)
1 Mice that have reached an endpoint; 2 Mice that were still alive at the end of the study.Pharmaceutics 2019, 11, x 10 of 13 
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For both cases, the same proton dose of 20 Gy was delivered to the implanted tumor located on the
left side of the mouse: (a,e) maximum intensity projections (MIP); (b,f) sagittal sections; (c,g) coronal
sections; and (d,h) transverse sections.
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4. Discussion
In this study, the combination of PT with TRT was explored using two different xenograft mouse
models. The therapy experiments showed comparable results of PT and TRT, applied at equal dose
or combined while using half of the dose. Interestingly, the results showed a trend of beneficial
effect when combining PT and TRT in the KB tumor model. This was demonstrated by significantly
increased TGDI2 and TGDI5 for mice receiving the combination therapy, as compared to the mice
treated with either PT or TRT, respectively. At this stage, there is no plausible explanation for these
findings. It was also not confirmed for the PC-3 PIP tumor-bearing mice, where an additive effect rather
than a synergistic effect was observed in the group of mice which received the combination therapy.
Interestingly, the dose calculation for the TRT was quite accurate even though there was a number of
uncertainties regarding the values on which the calculation was based. This concerns the exact quantity
of injected activity, inter-individually variable distribution profiles of the radioligand and potentially
inhomogeneously distributed activity in the tumor tissue. The calculation of the absorbed dose to
tumors after radionuclide therapy should, thus, be regarded as an approximation rather than an exact
dose calculation. This is in clear contrast to PT, where the absorbed dose can be exactly determined.
The phenomenon of tissue activation by proton irradiation and, consequently, the production
of short-lived PET radionuclides was previously investigated and the production of short-lived PET
radionuclides demonstrated [25]. It was found that the emitted positrons predominantly stemmed
from 15O, while 11C contributed to a smaller extent for the first ~9 min after irradiation. At later time
points (>10 min after proton irradiation), 11C appeared to be the predominant source of positron
emission, while the production of 13N played a minor role in this regard [25]. The major nuclear
reaction channels for proton-induced positron emitter production were previously reported in the
literature (Table S3) [25]. The production of 15O occurs via the 16O(p,pn)15O nuclear reaction, whereas
the production of 11C can occur by different nuclear reactions depending on the proton energy [25]. In
the study presented herein, visualization of activated tissue was successfully achieved immediately
after proton irradiation of the tumors. The results demonstrate the feasibility of precisely irradiating
small tumor xenografts with protons, without affecting neighboring healthy tissue.
Given that PT is a modality for loco-regional treatments, whereas TRT is for systemic treatment of
oligo-metastatic cancer patients, their combination may be both beneficial as well as complimentary.
As an example, lung cancer, as the leading cancer killer worldwide, could profit from such combination
therapy. In contrast to external photon beam therapy, PT of lung cancer patients has shown relatively
low rates of toxicity, however, the survival benefits have been unclear [26]. This may be due to the
existence of untreated distant metastases. The metastatic disease could be addressed by TRT using
therapeutic radionuclides (e.g., 177Lu, 225Ac) and a ligand that targets an appropriate tumor-associated
cell surface marker, such as the FR or the somatostatin receptor.
In this study, the foundation has been laid for future preclinical studies with mice to investigate the
concept of combining PT and TRT. In this regard, it would be of interest to investigate mouse models
not only with a solid tumor, but also with metastases to evaluate whether combining localized therapy
(PT) and systemic therapy (TRT) would complement each other in a clinically-relevant patient situation.
Other than the question with regard to the size of tumor lesions and accessibility for the relevant
radiation dose to be delivered, the topic of radiobiological and immunological effects as a response
to different radiation types has not yet been extensively investigated. It may be of high importance,
however, in view of a future clinical translation. Understanding the dose response of tumor cells
and the tumor microenvironment and normal tissue, respectively, has received renewed interest,
particularly in view of combination therapies with immunological approaches [27]. The same holds
true for TRT, where different types of particle radiation (α, β−, and Auger electrons) are being studied
with regard to their radiobiological effects in tumor tissue [28]. In future, it is planned to explore and
compare the therapy concepts in this regard using syngeneic and spontaneous tumor mouse models,
with an intact immune system, enabling the investigation of immunological responses to different
radiation modalities.
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5. Conclusions
In this preclinical pilot study, additive, or even a trend of synergistic effects depending on the
tumor xenograft type, have been demonstrated by combining PT and TRT. The current study has
laid essential foundations for future research regarding combination therapies of different radiation
therapies, as well as regarding a better understanding of radiobiological effects of these and further
radiation types. The research, which we intend to pursue in future, may be fundamental to identifying
the most effective application scheme of these combinations as an essential precondition in view of a
clinical translation.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/9/450/s1:
Methods of cell culture, set-up of irradiation station, methods for preparation of the radioligands for TRT
and PET/CT imaging; Figure S1: Chemical structures of the tumor targeting agents (folate and PSMA-617);
Figure S2: Sketch of the procedure of PET/CT imaging immediately after proton irradiation. Tables S1 and S2:
previously-published biodistribution data of the radioligands; Table S3. Major nuclear reaction channels for
proton induced positron emitter productions.
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